Somewhat Favorable Media Coverage Extremely Likely to Impact Akebia Therapeutics (NASDAQ:AKBA) Stock Price
Press coverage about Akebia Therapeutics (NASDAQ:AKBA) has trended somewhat positive recently, Accern Sentiment reports. Accern ranks the sentiment of media coverage by analyzing more than 20 million blog and news sources. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores nearest to one being the most favorable. Akebia Therapeutics earned a news sentiment score of 0.00 on Accern’s scale. Accern also gave press coverage about the biopharmaceutical company an impact score of 100 out of 100, indicating that recent media coverage is extremely likely to have an impact on the stock’s share price in the next few days.
These are some of the media headlines that may have effected Accern Sentiment Analysis’s scoring:
- Akebia Therapeutics, Inc. (AKBA) Set to Announce Earnings on Monday – ExpressNewsline (expressnewsline.com)
- Wall Street Consensus Watch on Akebia Therapeutics, Inc. (NASDAQ:AKBA) – Evergreen Caller (evergreencaller.com)
- Buy Consensus rating on Healthcare Stock: ReWalk Robotics Ltd. (RWLK) ,Akebia Therapeutics, Inc. (AKBA) – Street Observer (press release) (streetobserver.com)
- Akebia Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4) – Business Wire (press release) (businesswire.com)
- Akebia Therapeutics, Inc. (AKBA) Receives Consensus Recommendation of “Buy” from Analysts (americanbankingnews.com)
Akebia Therapeutics (NASDAQ:AKBA) traded up 4.29% on Tuesday, reaching $13.62. 278,688 shares of the company traded hands. The firm has a 50 day moving average of $14.28 and a 200-day moving average of $11.72. Akebia Therapeutics has a one year low of $7.16 and a one year high of $16.54. The stock’s market capitalization is $249.25 million.
Akebia Therapeutics (NASDAQ:AKBA) last released its earnings results on Tuesday, May 9th. The biopharmaceutical company reported ($1.15) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.15) by $1.00. The business had revenue of $20.87 million for the quarter, compared to analyst estimates of $16.50 million. On average, analysts anticipate that Akebia Therapeutics will post ($3.46) EPS for the current year.
A number of equities analysts have recently commented on AKBA shares. JMP Securities raised their price objective on shares of Akebia Therapeutics from $19.00 to $21.00 and gave the stock an “outperform” rating in a report on Wednesday, April 26th. HC Wainwright raised their price objective on shares of Akebia Therapeutics from $18.00 to $21.00 and gave the company a “buy” rating in a research report on Thursday, April 27th. Needham & Company LLC restated a “buy” rating and issued a $18.00 price objective (up previously from $14.00) on shares of Akebia Therapeutics in a research report on Thursday, April 27th. Aegis raised their target price on shares of Akebia Therapeutics from $21.00 to $25.00 and gave the company a “buy” rating in a research note on Friday, April 28th. Finally, UBS AG reaffirmed a “buy” rating and issued a $17.00 target price (up previously from $12.00) on shares of Akebia Therapeutics in a research note on Friday, May 5th. One investment analyst has rated the stock with a sell rating, three have assigned a hold rating and six have assigned a buy rating to the company. The company presently has a consensus rating of “Buy” and a consensus target price of $18.25.
In other news, Director Muneer A. Satter bought 1,034,482 shares of the firm’s stock in a transaction on Wednesday, July 5th. The stock was acquired at an average price of $14.50 per share, with a total value of $14,999,989.00. The acquisition was disclosed in a filing with the SEC, which is accessible through the SEC website. Corporate insiders own 8.67% of the company’s stock.
Akebia Therapeutics Company Profile
Akebia Therapeutics, Inc is a biopharmaceutical company. The Company focuses on the development and commercialization of therapeutics based on hypoxia-inducible factor (HIF) biology. The Company’s lead product candidate, vadadustat, is indicated for the treatment of anemia in chronic kidney disease (CKD).
Receive News & Stock Ratings for Akebia Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Akebia Therapeutics Inc. and related stocks with our FREE daily email newsletter.